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Homology models for the PERB11 multigene family
Gareth Chelvanayagam1, Antony Monaco2, John Philippe Lalonde2,
Guan K Tay2 and RL Dawkins2
Background: PERB11 is a multicopy polymorphic gene family found in
association with HLA Class I genes within the major histocompatibility complex
(MHC). Although its function is unknown, PERB11 has sequence similarities to
HLA Class I and other related proteins. To explore the possible functional roles
for PERB11, homology models have been constructed using both HLA Class I
and Class I-like protein structures as templates.
Results: The models show that PERB11.1 appears to have an unusual
distribution of charged residues that potentially give the molecule a distinct
polarity. Furthermore, a cluster of negatively charged residues in the traditional
P2 site may form a novel binding site for a positively charged ligand such as a
metal ion or complex. Other charged residues line the floor and walls of the cleft
and are able to form salt bridges, reminiscent of the closed cleft of the
Class I-like mouse neonatal Fc receptor structure. The closely related
PERB11.2 family has a different arrangement of charged residues in the cleft,
but these residues are still able to form salt bridges. Unlike HLA Class I, the
majority of polymorphic positions in the PERB11 family occur outside the cleft
and on the surface of the molecule.
Conclusions: Homology models for PERB11 suggest that the structure is
capable of associating with β2 microglobulin or a similar molecule. Furthermore,
not all of the potential glycosylation sites suggested by the PERB11 sequences
appear viable. Importantly, the models suggest that the molecule has a less
accessible cleft than HLA Class I and is not, therefore, able to bind peptides.
Other small ligands, including metal ions, might be bound, however.
Introduction
PERB11 (or MIC) is a gene family with multiple copies
located within the major histocompatibility complex
(MHC) [1,2]. Recent studies suggest that the PERB11
family may have similarities to the human leucocyte
antigen (HLA) Class I genes in that some genes are
expressed but others might only be pseudogenes or even
just gene fragments [3] and that copies of the gene appear
to be physically associated with HLA Class I genes [4].
Also, like Class I genes, PERB11 genes can be highly poly-
morphic [5–7]. The function of expressed PERB11 molec-
ules is unknown, but the putative amino acid sequence
shares ~30% identity with HLA Class I molecules from
various species as well as with other HLA Class I-like mol-
ecules, such as the mouse neonatal Fc receptor [8], human
hereditary haemochromatosis susceptibility gene (HFE)
[9], and human Zn-α2-glycoprotein (Znα2G; [10]).
Classical Class I molecules bind and present short peptide
fragments, usually nine amino acids in length, on the cell
surface for recognition by T-cell receptor complexes
(TCRs) [11]. The crystal structures of the extracellular
portion from several human [12–22] and mouse molecules
[23–26] have been determined and all show a similar
structure consisting of three covalently bound domains.
The α1 and α2 domains each consist of four β strands,
above which rests a long irregular α-helical structure. Both
these domains pack together to form an eight-stranded
sheet with the helices lying antiparallel to one another
above the sheet. The peptide-binding cleft is formed by
the space between the two helices. The α3 domain is
immunoglobulin like and packs beneath the sheet floor.
Comparison of the MHC–peptide complexes has shown
that peptides bind in a canonical manner in the cleft
[14,27,28]. The ends of the peptide are held in place by
hydrogen bonds between conserved amino acids (Tyr7,
Tyr84, Thr143, Trp147, Tyr159 and Tyr171) in the HLA
molecule and the backbone of the peptide, and the
central part of the peptide bulges out of the cleft and is
recognised by the CDR3 loops of TCRs [29,30].
Some Class I-like MHC molecules are known to bind
N-formylated peptides [31], but the function of other such
molecules remains unknown. The crystal structure of the
rat neonatal Fc receptor (FcRn) is similar overall to classi-
cal Class I molecules, but it has been shown to have a
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‘closed’ cleft that is unable to bind peptides [8]. Notably,
the FcRn lacks the tyrosine residues implicated in peptide
binding in classical Class I molecules. PERB11 sequences
also lack these residues leading to the proposition that the
PERB11 structure is similar to that of the FcRn [5].
The aim of this work is to construct an atomic model for
PERB11, based on the crystal structures of the classical
HLA and the FcRn, to examine potential functions. The
open or closed cleft and the functional involvement of the
polymorphic positions found in previous studies are to be
considered. The results favour a more closed cleft and
therefore do not support a role for PERB11 in peptide
presentation.
Results
Methods
The amino acid sequence of human PERB11.1–8.1 [5] was
aligned with the sequences of classical Class I molecules,
for which the crystal structures are known, as well as with
the sequence for the FcRn and sequences for HFE [9] and
Zn-α2-glycoprotein [10]. An initial alignment was obtained
using CLUSTAL W [32]. Subsequent manual adjustments
were required, making use of the superposition of the
structures of FcRn and the mouse HLA Class I homolog,
H-2Kb [8]. The amino acid sequence at the beginning of
the α2 domain is difficult to align for PERB11. An inser-
tion was therefore created in the N-terminal portion of this
domain because the extra loop region in this vicinity of the
structure would occupy a similar place to that of the inser-
tion found in the mouse HFE orthologue (Hfe) sequence.
The final alignment is presented in Figure 1.
Based on this alignment, two separate models were made
for human PERB11.1–8.1 using either FcRn [8] or HLA-
B*5301 [22] as a template. Initial models were constructed
with the HOMOLOGY module from the Insight Package
(Biosym Technologies, San Diego, USA). Tentative loop
regions were assigned by generating several possible
structures using the loop-generate command with various
parameters and choosing the one that complemented the
models well — hydrophobic residues were mostly buried
and, where possible, salt links were formed — and
included a low root mean squared (rms) deviation
between the splice sites of the model and the loop. The
initial models were then refined by first adding and relax-
ing hydrogen atoms; the relaxation step was performed
with the DISCOVER program from the same package.
During refinement, all heavy atoms were fixed and 100
cycles of steepest descent minimisation were performed.
Next, loop regions were subjected to a conformational
search with molecular dynamics (MD). Fixing all non-loop
heavy atoms to their initial positions and tethering the Cα
atoms of the loops with a force constant of 200 kcal/mol,
the system was brought to equilibrium using 500 dynamic
steps and was then run for five cycles of 200 steps, initially
at 600K. After every cycle the temperature was reduced
by 40K and the forcing constant reduced by 50 kcal/mol.
Snapshots of the trajectory were recorded at the end of
each cycle. The snapshots were then minimised as before
until the maximum derivative was < 0.1 kcal/mol. The
snapshot with the lowest energy was then subjected to a
further 200 steps of MD at 300K with no constraints and
was further minimised using 100 steps of steepest descent
minimisation followed by conjugate gradients minimisa-
tion until the maximum derivative was < 0.01 kcal/mol. No
cross or Morse terms were used during the calculations,
which were done in vacuum with a distance-dependent
dielectric constant.
The final models were then examined with the PROCHECK
program [33] to identify residues with any serious atomic
overlaps or bad geometry that were not present in the tem-
plate structures. Such residues were present throughout the
structure, a consequence of the low levels of sequence
identity. Residues involved in such interactions were first
adjusted manually, by rotating the sidechain torsion angles,
and then the whole structure was again refined as before.
This process was iterated until models with reasonable
geometry were obtained. The final models are discussed
below and are available from the authors on request.
Sequence alignment
In homology modelling, the selection of a suitable align-
ment between the target and the template sequence is of
paramount importance. Several alignments have previ-
ously been proposed for both the PERB11 and the HFE
protein sequences with both classical Class I and Class I-
like sequences [1,2,7,9]. The alignment shown in Figure 1
is similar to most, although some details vary. Included in
the alignment are the sequences of all Class I molecules of
known structure. In addition, the sequences for HFE, Hfe
and Znα2G are included because, from the alignment,
they appear to be Class I-like structures. Parts of the align-
ment can readily be anchored by conserved residues, such
as Tyr7, Ser13, Pro45, Trp49, Trp59, Gln91, Cys96,
Gly114, Trp127, Cys164, Leu172, Leu179, Cys202, Pro209,
Gly238, Trp245, Cys259 and His263. But other regions
remain difficult to align, particularly around the N termi-
nus of the α2 helix and the stretch of residues between
amino acids 220 and 230. From the alignment, PERB11.1
shows an overall sequence identity of ~24% to the HLA
Class I-like sequence of FcRn (34% α1 domain; 22% α2
domain; 24% α3 domain) and ~30% to the sequences of
classical HLA Class I structures (34% α1 domain; 23% α2
domain; 35% α3 domain). The HFE sequence shows
~29% identity with FcRn and ~40% identity with the clas-
sical Class I sequences. Thus, both PERB11.1 and HFE
show a stronger similarity to classical Class I sequences
than to the FcRn, albeit primarily in the α3 domain. But
the majority of the insertions and deletions in these two
sequences match exactly those of FcRn.
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Model evaluation
Overall the geometry of the two models for PERB11.1–8.1
is plausible. The positions of conserved residues in the
sequence alignment seem well placed and support a
Class I-type fold for the PERB11 family. There are no
serious stereochemical clashes, although the molecule
does contain some strained omega angles as determined
by the PROCHECK program [33]. The model cannot, there-
fore, be considered to be highly refined. Nonetheless,
these angles are confined around the loop regions where
insertions and deletions were introduced into the models
and these regions (Table 1) are of lower reliability. As
pointed out above, the N-terminal sequence of the α2
domain helix is difficult to align with the templates and
therefore this region is also questionable. But some
support for the chosen alignment comes from working
backwards from the conserved cysteine residue at position
164. Furthermore, in the model the bulky sidechain of
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Figure 1
        1    .........+.........+.........+........  .+.........+.........+.........+.........+..... 85
               eeEEEEEEEEE       eEEEEEEE  EEEEEEEE       EE HHHHHh   hhHHHHHHHHHHHHHHHHHHHHHHHHHHh
 FcRn      AEPRLPLMYHLAAVSDLSTGLPSFWATGWLGAQQYLTYNN--LRQEADPCGAWIWENQVSWYWEKETTDLKSKEQLFLEAIRTLENQIN-----------
 FcRbh     AESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNS--LRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGP-----------
 H-2Kb     --GPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQ-EGPEYWERETQKAKGNEQSFRVDLRTLLGYYNQSKG-------
 H-2Db     --GPHSMRYFETAVSRPGLEEPRYISVGYVDNKEFVRFDSDAENPRYEPRAPWMEQ-EGPEYWERETQKAKGQEQWFRVSLRNLLGYYNQSAG-------
 A*0201    --GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQ-EGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEA-------
 A*6801    --GSHSMRYFYTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQ-EGPEYWDRNTRNVKAQSQTDRVDLGTLRGYYNQSEA-------
 B*2705    --GSHSMRYFHTSVSRPGRGEPRFITVGYVDDTLFVRFDSDAASPREEPRAPWIEQ-EGPEYWDRETQICKAKAQTDREDLRTLLRYYNQSEA-------
 B*3501    --GSHSMRYFYTAMSRPGRGEPRFIAVGYVDDTQFVRFDSDAASPRTEPRPPWIEQ-EGPEYWDRNTQIFKTNTQTYRESLRNLRGYYNQSEA-------
 B*5301    --GSHSMRYFYTAMSRPGRGEPRFIAVGYVDDTQFVRFDSDAASPRTEPRPPWIEQ-EGPEYWDRNTQIFKTNTQTYRENLRIALRYYNQSEA-------
 PERB11    --EPHSLRYNLTVLSWDGSVQSGFLAEVHLDGQPFLRYDR--QKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKE-----------
 HFE       LLRSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFYDH--ESRRVEPRTPWVSSRISSQMWLQLSQSLKGWDHMFTVDFWTIMENHNHSK--------
 Znα2G     QDGRYSLTYIYTGLSKHVEDVPAFQALGSLNDLQFFRYNS--KDRKSQPMGLWRQV-EGMEDWKQDSQLQKAREDIFMETLKDIVEYYNDSN--------
 Hfe       PPRSHSLRYLFMGASEPDLGLPLFEARGYVDDQLFVSYNH--ESRRAEPRAPWILEQTSSQLWLHLSQSLKGWDYMFIVDFWTIMGNYNHSKVTKLGVVS
                   *     *                                 *   *         *
       86  ....+.........|. ........+.........+.........+.........+.........+.........+.........+... ......+.. 182
              EEEEEEEEEE     eEEEEEEEEE  EEEEEEE    EEEE       HHHHHHHHHHHhh HHHHHHHHHHH HHHHHHHHHhHHHH
 FcRn      GTFTLQGLLGCELAPD-NSSLPTAVFALNGEEFMRFNPRTGNWSGE-----WPETDIVGNLWMKQPEAARKESEFLLTSCPERLLGHLERGRQNLEWKE
 FcRnh     --YTLQGLLGCELGPD-NTSVPTAKFALNGEEFMNFDLKQGTWGGD-----WPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKE
 H-2Kb     GSHTIQVISGCEVGSDGRLLRGYQQYAYDGCDYIALNEDLKTWTAA-----DMAALITKHKWEQAGE-AERLRAYLEGTCVEWLRRYLKNGNATLLRTD
 H-2Db     GSHTLQQMSGCDLGSDWRLLRGYLQFAYEGRDYIALNEDLKTWTAA-----DMAAQITRRKWEQSGA-AEHYKAYLEGECVEWLHRYLKNGNATLLRTD
 A*0201    GSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAA-----DMAAQTTKHKWEAAHV-AEQLRAYLEGTCVEWLRRYLENGKETLQRTD
 A*6801    GSHTIQMMYGCDVGSDGRFLRGYRQDAYDGKDYIALKEDLRSWTAA-----DMAAQTTKHKWEAAHV-AEQWRAYLEGTCVEWLRRYLENGKETLQRTD
 B*2705    GSHTLQNMYGCDVGPDGRLLRGYHQDAYDGKDYIALNEDLSSWTAA-----DTAAQITQRKWEAARV-AEQLRAYLEGECVEWLRRYLENGKETLQRAD
 B*3501    GSHIIQRMYGCDLGPDGRLLRGHDQSAYDGKDYIALNEDLSSWTAA-----DTAAQITQRKWEAARV-AEQLRAYLEGLCVEWLRRYLENGKETLQRAD
 B*5301    GSHIIQRMYGCDLGPDGRLLRGHDQSAYDGKDYIALNEDLSSWTAA-----DTAAQITQRKWEAARV-AEQLRAYLEGLCVEWLRRYLENGKETLQRAD
 PERB11    GLHSLQEIRVCEIHED-NSTRSSQHFYYDGELFLSQNVETEEWTVPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLE-SSVVLRRRV
 HFE       ESHTLQVILGCEMQED-NSTEGYWKYGYDGQDHLEFCPDTLDWRAA-----EPRAWPTKLEWERHKIRARQNRAYLERDCPAQLQQLLELGRGVLDQQV
 Znα2G     GSHVLQGRFGCEIENN-RSSGAFWKYYYDGKDYIEFNKEIPAWVPF-----DPAAQITKQKWEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILDRQD
 Hfe       ESHILQVVLGCEVHED-NSTSGFWRYGYDGQDHLEFCPKTLNWSAA-----EPGAWATKVEWDEHKIRAKQNRDYLEKDCPEQLKRLLELGRGVLGQQV
                *    *                  *            *                                    *   *   *      *
      183  .......+.........|.........+.........+.........+.........+.........+.........+.........+.... 274
             EEEEEEEEe   EEEEEEEEEEE     EEEEEE  EE      EEEEeEE     EEEEEEEEEE      EEEEEE       EEE
 FcRn      PPSMRLKARPGNSGSSVLTCAAFSFYPPELKFRFLRNGLA--SGSGNCST-GPNGDGSFHAWSLLEVKRGDEHHYQCQVEHEGLAQPLTVDL
 FcRnh     PPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLA--AGTGQGDF-GPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVEL
 H-2Kb     SPKAHVTHHSRPEDKVTLRCWALGFYPADITLTWQLNGEE-LIQDMELVETRPAGDGTFQKWASVVVPLGKEQYYTCHVYHQGLPEPLTLRW
 H-2Db     SPKAHVTHHPRSKGEVTLRCWALGFYPADITLTWQLNGEE-LTQDMELVETRPAGDGTFQKWASVVVPLGKEQNYTCRVYHEGLPEPLTL--
 A*0201    APKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGED-QTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRW
 A*6801    APKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGED-QTQDTELVETRPAGDGTFQKWVAVVVPSGQEQRYTCHVQHEGLPKPLEE--
 B*2705    PPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGED-QTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRW
 B*3501    PPKTHVTHHPVSDHEATLRCWALGFYPAEITLTWQRDGED-QTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRW
 B*5301    PPKTHVTHHPVSDHEATLRCWALGFYPAEITLTWQRDGED-QTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRW
 PERB11    PPMVNVTRSEASEGNITVTCRASSFYPRNITLTWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPS
 HFE       PPLVKVTHHVTSSVTT-LRCRALNYYPQNITMKWLKDKQPMDAKEFEPKDVLPNGDGTYQGWITLAVPPGEEQRYTCQVEHPGLDQPLIVIW
 Znα2G     PPSVVVTSHQAPGEKKKLKCLAYDFYPGKIDVHWTRAGEV-QEPELR-GDVLHNGNGTYQSWVVVAVPPQDTAPYSCHVQHSSLAQPLVVPW
 Hfe       PTLVKVTRHWASTGTS-LRCQALDFFPQNITMRWLKDNQPLDAKDVNPEKVLPNGDETYQGWLTLAVAPGDETRFTCQVEHPGLDQPLTASW
                              * *    *                           *      *              *   * Folding & Design
A multiple sequence alignment of PERB11.1 with the major
histocompatibility complex (MHC) molecules of known structure and
the sequences of mouse and human hereditary haemochromatosis
susceptibility genes (Hfe and HFE, respectively) as well as the
sequence of Zn-α2-glycoprotein (Znα2G). Sequence numbering
follows PERB11.1. Dashes indicate relative insertions or deletions and
asterisks denote positions where the alignment is anchored by
conserved residues. Secondary structure is indicated above the
alignment: E, residues in a β strand; H, residues in an α helix; e and h,
variability between the secondary structures for FcRn and B*5301.
Trp127 is directly adjacent to Leu146 allowing the simul-
taneous variation that occurs for residues Ser127 and
Trp146 in the PERB11.2 (MICB) sequence [6]. Also, the
helical structure places charged and polar residues on the
surface of the molecule while burying most hydrophobic
residues. One notable exception is for Lys152, which pro-
jects into the α1/α2 helix interface to form a salt link with
Glu92 at the base of the cleft.
The rms deviations between the α1, α2 and α3 domains
of the two PERB11 models generally appear consistent
with the rms deviation between the template structures
over the equivalent regions. Superimposing all residues
that are not involved in loop regions in either model, the
PERB11 α1 domains differ by 3.6 Å (over residues 2–36,
42–50 and 57–81) compared to a difference of 3.8 Å for
the same residues in FcRn and B*5301. Similarly, dif-
ferences of 2.2 Å for the PERB11 models over the α2
domain (residues 89–97, 104–129, 134–146 and 154–171)
and 2.0 Å for the α3 domain (residues 179–219, 228–229
and 236–274) are comparable to the differences in the
template molecules, 1.6 Å and 1.4 Å, respectively. Inter-
estingly, for both models, the cleft becomes more closed
during the refinement process. It is also noteworthy that
despite lower sequence identity in the α2 domains, the
rms differences for these regions are lower than for the
α1 domains.
A number of hydrophobic residues are solvent exposed:
Val18, Leu12, Leu23, Val53, Met75, Leu87, Ile93, Ile98,
Leu116, Phe145, Met151, Leu165, Val176, Met185, Val221,
Leu223, Leu234 and Val272. This is to be expected, how-
ever, given the quaternary interactions formed by Class I
and Class I-like molecules with other molecules such as
β2 microglobulin (β2m), cluster designation (CD8), TCRs
or the Fc portion of IgG. Importantly, there are no buried
charged residues with the exception of those in the puta-
tive active site and Glu92, Arg94 and Lys152, which form
salt links in the Class I-like model. All in all, both models
can be regarded as reasonable and of suitable quality to
evaluate some of the possible functions of the PERB11
family of proteins.
Model features
As described previously, the overall structures of FcRn and
classical Class I molecules are very similar [8]. The largest
differences are both the repositioning of the α1 helix
towards the α2 helix and the bending of the α2 helix in
FcRn, closing off the classical peptide-binding cleft. Corre-
spondingly, both the Class I and Class I-like models for
PERB11 are also very similar (Figure 2) and features found
in one model are usually present in the other model. The
loop conformations are different, but these regions must be
treated as less reliable. Unless explicitly stated hereafter,
further discussion pertains to both models.
Perhaps the most striking feature of the models is the
clusters of charged residues distributed mostly on the
surface of the molecule. The location of Glu92 and Arg94
at the base of the cleft is surprising in the Class I-like
model, because these residues become buried but are able
to form a salt link. It would be intuitive to alter the align-
ment by one residue to flip the strand and point these
residues to the outside of the molecule. This would,
however, result in the loss of the conserved disulphide
bond between Cys96 and Cys164. The interior walls of
the cleft surrounding the traditional P2 site of classical
Class I molecules are lined by the negatively charged
residues Glu62, Asp65, Asp163 and Glu167. Above these
residues, arching over from the top of the helices, are posi-
tively charged residues Lys57, Arg61, Arg64 and Arg170.
Above the P9 site, at the top of the helices, Asp72, Glu148
and Asp149 form a negatively charged cluster. The stretch
of residues between strands three and four is particularly
positively charged: Arg35, Arg38, Lys40, Arg42 and Lys44.
In contrast, the loops outside the α2 helix are quite nega-
tively charged: Glu1, Glu100, Asp101, Glu123, Glu125
and Glu126. This would appear to give the molecule a dis-
tinct net polarity. Both positive and negative charges do,
however, occur on either side of the models. Salt bridges
that can be formed in the cleft of the Class I-like model
include interactions between Arg61 and Asp163, Arg61
and Glu167, Arg94 and Asp65, Arg94 and Glu92, Lys152
and Glu92, Lys152 and Asp72, Lys71 and Asp72, and
Lys72 and Asp149. More than half of the cleft is formed
by polar residues.
Another interesting feature of the models is a group of aro-
matic residues clustered around the traditional P9 site of
the cleft. Phe110, Tyr112, Phe117, Trp127 and Phe145 all
become less solvent exposed in the Class I-like model and
add to a hydrophobic core. Other hydrophobic residues are
also of interest. The occurrence of Met75 and Met151 on
the top of the α1 and α2 helices, respectively, is note-
worthy. These hydrophobic residues are fully solvent
exposed and may implicate the upper surface of PERB11 as
an interface region between other molecules. Position 151
is highly polymorphic and in the PERB11.1–65.1 sequence
methionine is replaced with valine, again a hydrophobic
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Table 1
Loop regions of low reliability in the models.
Loop Classical Class I Class I-like
1 37–41 130–138
2 51–56 173–178
3 82–88 222–227
4 98–103 230–235
5 130–138 130–138
6 147–152
7 172–177
8 220–225
residue but with a smaller sidechain. MHC Class I molec-
ules bind TCRs on this surface in a diagonal orientation
that involves residues at position 75, but not quite those at
position 151 [29,30]. A low-resolution crystal complex of
FcRn with Fc localises the binding site for Fc to the side of
FcRn [34], which is considerably different to the equivalent
structure in the MHC Class I molecule. The relative inser-
tion between strand eight and the α2 helix in PERB11
alters the conformation of the Fc binding site in the respec-
tive model, suggesting that PERB11 may have a novel
recognition surface for interacting with other molecules,
possibly involving Met75 and Met151.
Polymorphic sites
A considerable number of allelic variants have been
identified for PERB11 in humans. Having initially been
identified independently by two groups, the family cur-
rently bears two names: PERB11 and MIC. A total of 31
PERB11.1/MICA nucleotide sequences have been reported
[5,7], but some of these are likely to have been duplicated
by the two different groups. At the amino acid level there
are only 22 unique sequences, with the following seq-
uence pairs potentially giving rise to the same products:
PERB11.1–18.2, MICA001; PERB11.1–7.1, MICA008;
PERB11.1–60.3, MICA008; PERB11.1–8.1, MICA008;
PERB11.1–46.1, MICA10; PERB11.1–62.1, MICA010;
PERB11.1–65.1, MICA011; PERB11.1–54.1, MICA012;
and PERB11.1–35.1, MICA016. These known alleles give
rise to polymorphisms in 24 separate residue positions in
the extracellular (α1–α3) domains (Table 2). Surprisingly,
unlike classical Class I gene products, there is very little
polymorphism located in the putative antigen-binding cleft
([5]; Figure 3). Only residues at three positions near this
vicinity vary (positions 145, 151 and 156) and only in very
few sequences. Almost all polymorphic positions are on
the surface of the models, where most variation in proteins
occur. Unlike the densely packed cores of proteins, resi-
dues on the surface of the molecule have much more con-
formational freedom and interact largely with solvent,
screening some physicochemical properties. Hence, such
positions can tolerate the presence of several different
residue types.
Because the relative positions of most polymorphic resi-
dues are similar in both models, the effect of the poly-
morphism is discussed below in the context of both
models. Arg6 projects downwards from the sheet floor, at
the periphery of the putative β2m interface. The substi-
tution to proline in PERB11.1–46.1 (PERB11.1–62.1,
MICA010) is destabilising for the sheet because the
hydrogen bond to His27 is lost and the mainchain is
buckled. But because this residue is close to the N termi-
nus of the protein and near the start of strand one, it is
likely that this substitution will be tolerated by the fold.
In the case of Trp14, which occurs at the very end of
strand one, because Trp14 is solvent exposed, a substitu-
tion to glycine is unlikely to be deleterious, even consid-
ering the large change in sidechain volume. Thr24 is
located on strand two, under the α1 domain helix.
Almost all of the polymorphic sequences have alanine at
this position, the exceptions being PERB11.1–18.2
(MICA001) and PERB11.1–54.1 (MICA012). In the
models, this polymorphic position is directly adjacent to
Tyr36, which can be substituted by cysteine. With
rearrangement of the loop between strands three and
four, it is possible that Cys36 may form a disulphide
bond with Cys41. The Thr24→Ala substitution may well
be a prerequisite for this as it increases the local flexibil-
ity of the molecule in this region by reducing the
sidechain volume at position 24.
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Figure 2
A stereo image showing a superposition of
the Cα trace of the α1 and α2 domains of
classical Class I (dashed line) and Class I-like
(solid line) models for PERB11. The backbone
atoms of residues Ser4–Leu12,
Pro22–Asp29, Pro32–Tyr36, Ala43–Pro45,
His88–Cys96, Gln108–Tyr112 and Leu118
were equivalenced and have an rms deviation
of ~1.0 Å.
N N
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Gly114 is in the loop between strands six and seven.
When substituted by arginine, its sidechain points down
from the sheet floor, into the putative β2m interface. This
position is directly adjacent to Gln91, which can also be
substituted by arginine. Thus, PERB11.1–57.1, MICA014
and MICA015 would all project an arginine into the puta-
tive β2m interface. Val122 and Glu125 are both on the
loop between strands seven and eight and are sequentially
close to Val129, although none of the sidechains are
directly adjacent in the models. The Val122→Leu substi-
tution is conservative, while the Glu125→Lys substitution
involves an exchange of charge. The latter position is on
the surface of the protein and so such a charge change
is not unusual. With the exception of PERB11.1–18.2
(MICA001) all the sequences have lysine at this position.
The Val129→Met substitution involves a large difference
in sidechain volume, but both residues are hydrophobic.
Because the substitution is on an edge strand of the sheet
floor it is likely that the additional sidechain bulk will pro-
trude out to the surface of the molecule, close to Met140.
The Met151→Val substitution occurs on the upper surface
of the α2 domain helix, at the crest of the major kink in the
helix. Despite being hydrophobic, the residue at this posi-
tion is fully exposed and may be involved in molecular
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Table 2
PERB11.1 polymorphism.
Position
PERB11/MICA 6 14 24 36 91 114 122 125 129 145 151
PERB11.1–18.2 R W T C Q G L K M F M
PERB11.1–7.1* A Y E V
PERB11.1–13.1 A Y E V L
PERB11.1–35.1 A Y E V
PERB11.1–44.1 A Y E V
PERB11.1–44.3 A Y V E V
PERB11.1–46.1 P A Y E V
PERB11.1–62.1 P A Y E V
PERB11.1–47.1* A Y E V
PERB11.1–52.1 A V E V
PERB11.1–54.1 E
PERB11.1–57.1 G A R E
PERB11.1–65.1* G A E V
PERB11.1–60.3* A Y E V
PERB11.1–8.1 A Y E V
MICA001 R W T C Q G L K M F M
MICA002 G A E
MICA003 A V E V
MICA004 A Y V E V
MICA005 A Y E V
MICA006 A Y V E V
MICA007 A E
MICA008 A Y E V
MICA009 A Y V E V
MICA010 P A Y E V
MICA011 G A E V
MICA012 E
MICA013 G A E V
MICA014 G A R E
MICA015 G A R E
MICA016 A Y E V
*Polymorphism beyond residue 181 is unknown.
156 173 175 176 181 206 210 213 215 221 251 268 271
H K G V T G W T S V Q S P
E
E S R I T R
E S S R I T L R
E S R I T R
E S R S R I T R
E S S R I T R
E S S R I T R
E
E S S R T
S R I T R
E
E S R I T R
H K G V T G W T S V Q S P
E S R S R T G
E S R S R T
S R T R
E S I S R T
E S R I T R
E S S R T
E S S R I T R
A
L
E R
E R
E S S R I T L R
recognition. Each of the polymorphic sites 173, 175, 176
and 181 occur at the end of the α2 helix and the α2/α3
domain–linker region. All sites are solvent exposed and
in each case the amino acid exchanges are conservative,
except for Thr181→Arg.
Interestingly, almost all of the polymorphic positions in the
α3 domain (residues 210, 213, 215, 221, 268 and 271) occur
on one surface of the domain, with positions 210, 213 and
215 all occurring on the third strand. The only exceptions
are Gly206→Ser and Gln251→Arg. Gly206→Ser, Trp210→
Arg and Ser215→Thr also appear to undergo simultaneous
variation, although it is likely that a glycine is required at
position 206 to allow local structural flexibility to accommo-
date the bulky tyrptophan sidechain at position 210. The
significance of the serine at position 215 is not obvious from
the models.
As a result of the differences between the open or closed
cleft templates, some polymorphic positions have different
consequences, depending on the template. For example,
Arg6 forms salt links with Asp29 and Glu97 in the non-clas-
sical Class I model, but because of the different orientation
of the end of strand 2 Arg6 does not form a salt link in the
Class I model. The PERB11.1–13.1 sequence has a leucine
at position 145 while all other sequences have a phenyl-
alanine. This substitution is conservative in the Class I-like
model, in that position 145 is partly buried between the
α1/α2 helix interface, but is not conservative in the Class I
model where this position is exposed. Similarly, His156 is
buried deep in the interface between the two helices in the
Class I-like model but is exposed at the base of the cleft in
the classical Class I model. Occurring midway along the α2
helix, His156 is exchanged for leucine in PERB11.1–54.1
(MICA012), a favourable exchange for a buried residue but
unfavourable for an exposed residue.
βb2 microglobulin binding
The models for PERB11 were constructed and refined in
the absence of β2m. To assess if PERB11 should permit
β2m binding, the putative β2m/PERB11 interface was
examined. Of the 26 residues forming the interface in the
FcRn molecule [8], only four residues (Gln91, Pro235,
Gln237 and Trp245) are conserved between PERB11,
FcRn and Class I MHC. Thr201 is also conserved between
PERB11 and FcRn, but not with classical molecules. Con-
versely, Thr10, Arg35 and Gln242 are conserved between
PERB11 and classical molecules, but not with FcRn. Most
of the remaining interface sites undergo conservative amino
acid replacements or partake in concerted exchanges in the
models. For example, with respect to FcRn the additional
volume required by the Val12→Leu exchange can be
accommodated by the adjacent Trp23→Leu exchange.
The Asn231→Asp exchange can be compensated for by the
Asp238→Asn exchange, and the Ala203→Arg replaces the
charge lost in the Lys189→Thr substitution. Likewise,
with respect to HLA Class I molecules, the Arg201→Thr
exchange can compensate for the Trp203→Arg substitu-
tion. Less conservative exchanges tend to take place at the
periphery of the interface region. Three exchanges appear
unfavourable: Ala111→Tyr, Phe205→Ser and Gly234→
Leu. A tryptophan residue at amino acid position 60 in
β2m occupies the space adjacent to Ala111 in the FcRn
molecule, and substitution of this residue to Tyr111 will
require at least some local structural adjustment to facilitate
binding. The Phe205 exchange occurs in concert with the
His242→Gln exchange, altering a local aromatic surface
region for a more polar one. The Gly234→Leu exchange
involves a large change in sidechain volume, but also occurs
in a region of diversity between FcRn and PERB11 in
that PERB11 incorporates a bulge as found in classical
Class I structures. Although the β2m interface region differs
between classical Class I, FcRn and PERB11 molecules,
PERB11 still appears to be able to bind either to β2m or
possibly some other molecule, because the surface in and
around the putative interface involves a number of exposed
hydrophobic residues (Val18, Leu12, Leu23, Leu87,
Ile93, Leu116, Met185, Leu234 and Val272). Further-
more, the polymorphic face of the α3 domain is located
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Figure 3
A ribbon diagram of the Class I-like model of PERB11 showing the
relative positions of polymorphic residues (dark sections).
(a) Polymorphic sites in the α1 and α2 domains. (b) Polymorphic sites
in the α3 domain.
(a)
(b)
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on the other side of the domain, away from the β2m inter-
face. Only two polymorphic positions occur in or around
the putative β2m interface, both of which could disrupt
β2m binding: Gly114→Arg and Gln91→Arg. The Gln91
exchange is of particular note because this residue is
usually conserved in HLA Class I molecules.
Glycosylation sites
Eight potential glycosylation sites have previously been
identified [5]. Each of the asparagine residues (positions
8, 56, 102, 187, 197, 211, 238 and 266) are on the surface
of the molecule and are thus accessible for glycosylation.
But Asn8 occurs on the lower surface of the sheet floor
and is at the periphery of the putative β2m interface, it
therefore becomes less accessible if β2m is bound. Thr58
is also buried, half a helical turn away from Asn56, dimin-
ishing the chances of Asn56 being glycosylated. Similar
situations exist for Asn102 and Thr104, where Thr104 is
also less solvent accessible. Thr213 is polymorphic as is
Thr268, so glycosylation of Asn211 and Asn266 would not
be ubiquitous.
Potential metal-binding site
As noted above, a remarkable feature of the non-classical
Class I model is the clustering of charged residues that lie
between the interface of the α1 and α2 helices. One group
of these charged residues involves Glu62, Asp65, Asp163
and Glu167, all of which cluster around the conventional
P2 site of classical Class I molecules. These four nega-
tively charged residues, in conjunction with Tyr7, His158
and Arg64, may form a binding site for a positively
charged ligand. The general positioning of these residues
shows a distinct similarity to a metal-binding site in man-
delate racemase [35], a member of an enzyme superfamily
that has evolved to catalyse proton abstraction from
carbon. Figure 4 shows that although the residues that
bind to and participate in the mandelate racemase active
site are oriented differently, they are also found in the
PERB11 model. The biggest discrepancy between the two
sites is the position of Lys164 in mandelate racemase com-
pared with Arg64 in PERB11; otherwise the sites are
remarkably similar. None of the residues in the vicinity of
this site are polymorphic. Furthermore, the model is
expected to be reliable in this region, the structure being
stabilised by the disulphide bond between Cys96 and
Cys164. Interestingly, if an additional disulphide were to
form between residues Cys36 and Cys41 in other PERB11
genetic products, this would further help to stabilise the
molecule around Cys36 and Cys41.
PERB11 gene families
As mentioned above, PERB11 (MIC) is a multigene family
that occurs over the Class I and central regions of the MHC.
Two members of this family, PERB11.1 and PERB11.2,
have been shown to be functional [5] and are located in the
region between HLA-C and the complement component
C4 gene (C4). This region has been implicated in suscepti-
bility to autoimmune diseases such as insulin dependent
diabetes mellitus and myasthenia gravis [36,37]. In con-
trast, PERB11.4, located telomeric of HLA-A, contains an
early stop codon at position 140 in the α2 domain. Accord-
ing to the models presented here, PERB11.4 is devoid of
the majority of residues that form the α2 helix, and thereby
lacks many residues that contribute to the classical antigen-
binding site structure. In addition, the conserved disul-
phide bond between Cys96 and Cys164 is not possible,
severely undermining the stability of the molecule. This
strongly suggests that PERB11.4 is a pseudogene.
The interlocus diversity between the sequences of
PERB11.1 and PERB11.2 molecules involves significant
changes to the putative active-site cleft. A total of 40 differ-
ences are noted between these two proteins at the amino
acid level in the extracellular domains. About a quarter of
these differences are located directly in the cleft. Interest-
ingly, many of the differences appear in small clusters in
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Figure 4
A stereo image of a manual superposition of
the active site from mandelate racemase onto
residues in the cleft of PERB11. Because no
templating was attempted, the superposition
may not be optimal.
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the PERB11.1 models. This suggests that these changes
have occurred in concert to maintain the integrity of the
fold. The substitution of Val26→Gly, Arg61→Thr, Arg64→
Glu, His158→Arg and Glu167→Lys all affect the putative
metal-binding site proposed in the non-classical Class I
model. Other changes in the cleft involve Trp127→Ser,
Leu146→Trp, Met160→His, Gln108→Arg and Gly68→
Glu. The Gln108→Arg exchange is of particular note
because this places yet another charged residue at the floor
of the cleft, along with Arg94 and Glu92. Furthermore, this
substitution is more easily accommodated in the open cleft
of the classical Class I model than in the non-classical Class
I-like model. Most differences between the families occur
on the surface of the molecules. Interestingly, the structure
at the N terminus of the α2 helix would appear to be able
to accommodate either Trp127 (PERB11.1) or Trp 146
(PERB11.2), but not both as in classical Class I structures.
Further differences have been described in the transmem-
brane and cytoplasmic domains and have lead to the sug-
gestion that molecules in these families are functionally
different [5]. The difference in the putative metal-binding
site would support this notion. Nonetheless, the lining of
the cleft with charged residues is a clear feature in both
PERB11.1 and PERB11.2.
Discussion
Previously, tentative schematic models for PERB11 were
presented using the HLA Class I molecule as a template
[2,7]. These models concentrated the polymorphism on
the outer edge of the putative antigen-binding cleft, bor-
dering on an invariant ligand-binding site. Generally, the
atomic models presented here support these findings,
although it is noted that the alignment used previously is
different from that used here and elsewhere [1,9].
Overall the gross features of classical and non-classical
Class I molecules are quite similar. The most striking dif-
ference, which has a very important functional conse-
quence, is the nature of the putative antigen-binding cleft.
Classical Class I structures have an ‘open’ cleft and can
bind short peptides [12,13], but the Class I-like structure
FcRn has a ‘closed’ cleft and does not bind peptides [8].
Previous sequence alignments of PERB11 [1] and HFE [9]
have prompted authors to suggest that these proteins adopt
a fold similar to that of the Class I-like FcRn. The align-
ment presented in Figure 1 supports this in that the place-
ment of most of the insertions and deletions in the
PERB11 sequence match almost exactly those in the FcRn
sequence. But the level of sequence identity is slightly
higher between PERB11 and HLA Class I sequences than
between PERB11 and the FcRn sequence. The α1 and α2
domains show similar levels of identity to both template
sequences and it is only the α3 domain that shows an
increase in identity of ~10% between PERB11 and classi-
cal Class I sequences. Consequently, this domain is
expected to appear more similar to Class I structures. One
argument for a more closed cleft is the formation of salt
bridges that form between the charged residues that line
the cleft. The lack of polymorphism at these positions sug-
gests that the identity of these residues must be conserved,
either for a functional or structural reason. A functional
reason would imply that all variants of the molecule bind
the same ligand, unlike the consequence of polymorphism
in classical Class I molecules. A structural reason would
support a more closed cleft. Interestingly, although the
charge distribution in the cleft alters in the PERB11 family,
the formation of salt bridges in the cleft is maintained,
further supporting a closed cleft.
HLA Class I molecules associate with the peptide trans-
porter TAP, and it has been postulated that the major site
of interaction between the mouse Class I antigen presen-
tation molecule H-2Dd and TAP involves the glutamate
residue at position 222 [38]. In PERB11, this corresponds
to Val221, a polymorphic residue localised within the poly-
morphic face of the α3 domain. This polymorphism may
signify that PERB11 does not associate with TAP and
does not, therefore, bind peptides in the classical sense,
again supporting a closed cleft.
The putative β2m binding region of PERB11 identified in
this article shows that it has a different amino acid compo-
sition to both that of FcRn and HLA Class I molecules.
Nonetheless, the occurrence of several hydrophobic resi-
dues and concerted exchanges in this vicinity in the
models support the notion that PERB11 is able to bind
β2m or a similar molecule. Surprisingly, it has recently
been reported that this may not be the case [39]. This
opens up the possibility that the PERB11 family may asso-
ciate with a different molecule or may pack the exposed
hydrophobic faces of the different domains together with a
unique orientation of the α3 domain. Dimerisation of
PERB11 or a radical conformation of the QSSRA insertion
may provide the explanation for this controversy.
Care must be taken so as not to over-interpret the accuracy
of the models because it has been shown that molecules
with ~30% sequence identity may still deviate from one
another by up to ~3.0 Å in core regions of the fold [40,41]
and it is likely that the PERB11 fold is a hybrid between
that of HLA Class I and the FcRn, with features from both.
The recently solved structure of CD1 [42] supports this.
The width of the cleft in CD1 is roughly the average of
that in the classical Class I and Class I-like FcRn molec-
ules. Furthermore, CD1 appears to have an α1 domain
helix more similar to that of a Class I molecule in that it is
slightly bowed, whereas the α2 helix appears more similar
to FcRn, although the N-terminal portion of the α2 helix
(α2H1) has a slightly different orientation. CD1 appears
unique in that the α1 domain helix is raised much higher
than in other molecules, providing a much deeper cleft. If
PERB11 is found to bind small ligands, CD1 may provide
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a better template molecule in that its cleft may also be
required to be deeper.
A more closed cleft is probable making the molecule a
potential receptor candidate [1]. One caveat is the lack of a
proline at position 164 in PERB11. The kink in the main-
chain direction induced by this residue has been impli-
cated in the formation of the closed cleft seen in FcRn [8],
and more recently in the CD1 cleft [42,43]. Although this
proline appears to affect the positioning of the middle
portion of the α2 helix (α2H2a), the relative location of
α2H1 is independent of the presence of this residue [43].
Thus, closed ends around α2H1 and α2H2b (the C-termi-
nal part of the α2 helix) are possible for PERB11, but the
absence of Pro164 brings into question the location of
α2H2a in the Class I-like model. Again, this suggests that
the actual structure of PERB11 is likely to be a hybrid of
both Class I and Class I-like structures. The absence of
proline at position 164 and the relative deletion, found only
in PERB11, two helical turns away, implicates a unique
α2 helix structure for PERB11 molecules. This deletion
may provide another structural mechanism to achieve a
closed cleft.
A clear feature of the cleft is its polarity. Out of ~30
residues that form the cleft, just over half have either polar
or charged sidechains. This would tend to rule out lipids,
which prefer a more hydrophobic environment, as puta-
tive ligands for PERB11. A potential metal-binding site
has been identified here that may be amenable to other
polar ligands. Small, polar, non-peptide ligands, such as
synthetic alkyl phosphates, have been found to be able to
stimulate γδ T cells [44,45] and would be consistent with a
more closed cleft. Thus, it is possible that PERB11 may
present such antigens to these T cells, although from the
models an appropriate docking site is unclear.
The fact that polymorphic residue positions occur on the
surface of the PERB11 molecule is not unusual because
this is where most alterations in proteins occur. Subtle
changes to the surface of the molecule may result in differ-
ent phenotypic behaviour in PERB11. This would become
important if PERB11 is a receptor. But alterations, such as
the occurrence of premature stop codons that result in the
lack of the cytoplasmic tail, are likely to produce more
obvious effects. The lack of such a domain may prevent the
molecule from being correctly processed, and PERB11
may, therefore, build up within the cell. The possible
metal-binding characteristics could also result in a build up
of iron as is found in the case of diseases such as haema-
chromatosis [9]. A further understanding of the immunolog-
ical role of PERB11 is potentially important. The present
work serves to highlight features that may be present in the
PERB11 molecule that can subsequently be tested experi-
mentally, thereby leading to a greater understanding of the
functional involvement of these molecules.
Note added in proof
Using immunoprecipitation and Western blotting, it has been suggested
that PERB11.1 may not associate with β2 microglobulin [46], but the
defect of polymorphism (see above) has not been addressed to date.
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